1-(4-fluoro-phenyl)-3-isopropyl-4-oxo-5-phenyl-4,5-dihydro-3H-pyrrolo[2,3-c]quinoline-2-carbaldehyde | 889878-49-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(4-fluoro-phenyl)-3-isopropyl-4-oxo-5-phenyl-4,5-dihydro-3H-pyrrolo[2,3-c]quinoline-2-carbaldehyde
• 英文别名: 1-(4-Fluorophenyl)-4-oxo-5-phenyl-3-propan-2-ylpyrrolo[2,3-c]quinoline-2-carbaldehyde；1-(4-fluorophenyl)-4-oxo-5-phenyl-3-propan-2-ylpyrrolo[2,3-c]quinoline-2-carbaldehyde
• CAS: 889878-49-3
• 化学式: C₂₇H₂₁FN₂O₂
• 分子量: 424.474
• InChiKey: RXCQNPICEQMDDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  42.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-fluoro-phenyl)-3-isopropyl-4-oxo-5-phenyl-4,5-dihydro-3H-pyrrolo[2,3-c]quinoline-2-carbaldehyde 在 lithium tri-t-butoxyaluminum hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以49%的产率得到1-(4-fluoro-phenyl)-2-hydroxymethyl-3-isopropyl-5-phenyl-3,5-dihydro-pyrrolo[2,3-c]quinolin-4-one
  参考文献：
  名称：

  Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors

  摘要：

  Using structure-based design, a novel series of conformationally restricted, pyrrole-based inhibitors of HMG-CoA reductase were discovered. Leading analogs demonstrated potent inhibition of cholesterol synthesis in both in vitro and in vivo models and may be useful for the treatment of hypercholesterolemia and related lipid disorders. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.097
• 作为产物：
  描述：

  3-(2-bromo-phenyl)-4-(4-fluoro-phenyl)-5-formyl-1-isopropyl-1H-pyrrole-2-carboxylic acid phenylamide 在 palladium diacetate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 caesium carbonate 作用下， 以 甲苯 为溶剂， 反应 20.0h， 以80%的产率得到1-(4-fluoro-phenyl)-3-isopropyl-4-oxo-5-phenyl-4,5-dihydro-3H-pyrrolo[2,3-c]quinoline-2-carbaldehyde
  参考文献：
  名称：

  WO2006/59210

  摘要：

  公开号：

文献信息

• WO2006/59210
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] FUSED BICYCLIC PYRROLS AS HMG-COA REDUCTASE INHIBITORS<br/>[FR] PYRROLS BICYCLIQUES FUSIONNES COMME INHIBITEURS DE LA REDUCTASE AS HMG-COA
  申请人：WARNER LAMBERT CO

  公开号：WO2006059210A2

  公开（公告）日：2006-06-08

  [EN] HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidenuc compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided.
  [FR] Composés de l'inhibiteur de la réductase HMGCo-A utilisés comme composés hypocholestérolémiques et hypolipidémiques. Compositions pharmaceutiques de ces composés, leurs procédés de préparation et d'utilisation.
• Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors
  作者：Jeffrey A. Pfefferkorn、Chulho Choi、Yuntao Song、Bharat K. Trivedi、Scott D. Larsen、Valerie Askew、Lisa Dillon、Jeffrey C. Hanselman、Zhiwu Lin、Gina Lu、Andrew Robertson、Catherine Sekerke、Bruce Auerbach、Alexander Pavlovsky、Melissa S. Harris、Graeme Bainbridge、Nicole Caspers

  DOI：10.1016/j.bmcl.2007.05.097

  日期：2007.8

  Using structure-based design, a novel series of conformationally restricted, pyrrole-based inhibitors of HMG-CoA reductase were discovered. Leading analogs demonstrated potent inhibition of cholesterol synthesis in both in vitro and in vivo models and may be useful for the treatment of hypercholesterolemia and related lipid disorders. (c) 2007 Elsevier Ltd. All rights reserved.